In PC12 cells incubated with PD318088 in a design including glucose/glucose oxidase, MEK inhibitors demonstrated similarly high cell death rates to the DMSO control. In SW480–7TFP, PD318088 produced a dose-dependent increase in TCF-Wnt reporter levels. In ACHN, PD318088 showed limited single-agent activity as assessed by cell viability. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cell death in PC12 cells
Cell-based study · PC12 cells (Neuroscreen-1 sub cell line) [1]
PC-12 cells were separately incubated with PD318088 (200 nM) for 1 h. Against oxidative stress induced by 0.01 units of glucose oxidase in glucose-supplemented medium for 12 h, MEK inhibitors demonstrate similar high cell death rates as to the DMSO control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 200 nM
- Exposure duration
- for 1 h
- Method
- incubated
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: glucose/glucose oxidase 0.01 units of glucose oxidase with one-fifth of the medium exchanged to high glucose DMEM. Compound effect isolated by the comparison: MEK inhibitors demonstrate similar high cell death rates as to the DMSO control.
Methods and source locations
Compound reported in the paper: PD318088
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Materials (S4); Methods > Cell Culture (S5); Methods > Cell Death Assay (S10, S12, S13, S18); Figure 1 legend (S44, S53)
percentage of dead cells: percentage of dead cells; comparator: DMSO control — Methods > Cell Death Assay (S10, S12, S18); Figure 1 legend (S53)
Dose-dependent increase in TCF-Wnt reporter levels
Cell-based study · SW480–7TFP [2]
In the SW480–7TFP model, treatment at different concentrations was evaluated against DMSO controls using TCF/Wnt-luciferase and CellTiterGlo signals. TCF-Wnt reporter levels increased in a dose-dependent manner.
Literature-Reported Treatment Conditions
- Treatment concentration
- different concentrations
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations
Compound reported in the paper: PD318088
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Trametinib is a potent activator of canonical Wnt signalling (S20, S21); Fig. 2 legend (S338, S339)
TCF/Wnt-luciferase and CellTiterGlo signals: TCF/Wnt-luciferase and CellTiterGlo signals; comparator: DMSO controls — Results > Trametinib is a potent activator of canonical Wnt signalling (S20, S21); Fig. 2 legend (S339)
Limited Single-Agent Activity in the ACHN Model
Cell-based study · ACHN [3]
Single-agent treatment in the ACHN model showed limited activity in the cell viability readout.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: PD318088
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Integration of transcriptomic and phosphoproteomic datasets reveals coordinated inhibition of the MAPK-ERK pathway (S63, S65)
cell viability: cell viability — Results > Integration of transcriptomic and phosphoproteomic datasets reveals coordinated inhibition of the MAPK-ERK pathway (S65)
